Extended Data Table 5 Safety summary

From: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

  1. EC+mFOLFOX6, encorafenib and cetuximab plus oxaliplatin, leucovorin, and 5-FU; N/A, not applicable; SOC, standard of care. * Other study intervention includes: irinotecan, oxaliplatin, leucovorin or levo-leucovorin, fluorouracil (bolus or infusion), capecitabine, and bevacizumab (as appropriate for the treatment group). † Sepsis (preferred term).
Back to article page